Neoadjuvant Weekly Paclitaxel and Biomarkers of Therapy Response
Status:
Recruiting
Trial end date:
2022-02-01
Target enrollment:
Participant gender:
Summary
The hypothesis of this study is that paclitaxel levels increase chromosomal instability (CIN)
in tumors and this is lethal to tumors that have pre-existing CIN. Treatment will be
administered on an outpatient basis. Paclitaxel will be initiated as standard infusions on
days 1, 8, and 15 of a 21-day cycle. Participants will continue with paclitaxel for cycles
2-4 prior to surgery.